Ovusense
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
£780k | Early VC | ||
£500k | Early VC | ||
N/A | £1.2m | Early VC | |
N/A | £881k | Early VC | |
£800k | Early VC | ||
N/A | £500k | Early VC | |
$2.6m Valuation: $4.0m | Series A | ||
N/A | Support Program | ||
$250k | Debt | ||
Total Funding | AUD13.6m |
Recent News about Ovusense
EditOvuSense operates in the fertility and health monitoring market, providing a clinically proven fertility tracker that predicts ovulation in real-time and confirms it with 99% accuracy. The company's core product, the OvuCore sensor, is designed to be worn overnight and inserted vaginally, similar to a tampon. This device serves women who are trying to conceive, including those with conditions like PCOS and endometriosis, by offering an 8-day fertile window to maximize the chances of pregnancy. OvuSense's business model revolves around direct-to-consumer sales through its website and mobile apps available on Apple App Store and Google Play. The company generates revenue through the sale of its fertility monitors and associated subscription services for ongoing support and data analysis. By providing accurate, real-time data, OvuSense helps women take control of their fertility journey, potentially reducing the time to conceive by up to 15 months compared to other methods.
Keywords: fertility tracker, ovulation prediction, real-time data, 99% accuracy, PCOS, endometriosis, direct-to-consumer, subscription services, health monitoring, pregnancy planning.